PERTH: NeuroScientific Biopharmaceuticals Ltd. (ASX:NSB) announced plans to acquire StemSmart™, a patented stem cell technology from Isopogen WA Ltd., aimed at developing treatments for immune-mediated inflammatory disorders, including refractory Crohn’s disease. The acquisition, subject to shareholder and regulatory approvals, includes binding agreements with key Isopogen shareholders holding 51.4% of the company’s shares. NeuroScientific will issue…